Novel Oral Anticoagulants in Atrial Fibrillation: Will the Benefit Outweigh the Cost?

被引：0
|
作者：
Goudevenos, John [1 ]
Pipilis, Athanasios [2 ]
Vardas, Panos [3 ]
机构：
[1] Ioannina Univ Hosp, Med Sch Ioannina, Dept Cardiol, Ioannina, Greece
[2] Hygeia Hosp, Dept Cardiol 1, Athens, Greece
[3] Heraklion Univ Hosp, Dept Cardiol, Iraklion, Greece
来源：
HELLENIC JOURNAL OF CARDIOLOGY | 2012年 / 53卷 / 02期
关键词：
Atrial fibrillation; novel anticoagulants; dabigatran; rivaroxaban; apixaban; cost-benefit; DABIGATRAN ETEXILATE; STROKE PREVENTION; SYSTEMIC EMBOLISM; SUBGROUP ANALYSIS; WARFARIN; RIVAROXABAN; ENOXAPARIN; APIXABAN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：137 / 141
页数：5
相关论文
共 50 条
  • [1] Risk and Benefit of Oral Anticoagulants in Atrial Fibrillation
    Zotova, I. V.
    Zateyshchikov, D. A.
    [J]. KARDIOLOGIYA, 2011, 51 (10) : 81 - 91
  • [2] Novel Oral Anticoagulants for Atrial Fibrillation
    Hankey, Graeme J.
    Eikelboom, John W.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2013, 15 (08)
  • [3] Novel oral anticoagulants for atrial fibrillation
    Mahtani, Kamal R.
    Heneghan, Carl
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [4] Novel oral anticoagulants for atrial fibrillation
    How, Choon How
    [J]. SINGAPORE MEDICAL JOURNAL, 2015, 56 (12) : 657 - 659
  • [5] Novel Oral Anticoagulants for Atrial Fibrillation
    Graeme J. Hankey
    John W. Eikelboom
    [J]. Current Atherosclerosis Reports, 2013, 15
  • [6] Warfarin or novel oral anticoagulants for atrial fibrillation?
    Larsen, Torben Bjerregaard
    Lip, Gregory Y. H.
    [J]. LANCET, 2014, 383 (9921): : 931 - 933
  • [7] Novel oral anticoagulants and atrial fibrillation in the elderly
    Hanon, Olivier
    [J]. GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT, 2013, 11 : 34 - 40
  • [8] Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
    Mendoza-Sanchez, Jose
    Silva, Federico
    Rangel, Lady
    Jaramillo, Linda
    Mendoza, Leidy
    Garzon, Jenny
    Quiroga, Andrea
    [J]. PLOS ONE, 2018, 13 (05):
  • [9] Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants
    Charalampos Kasmeridis
    Stavros Apostolakis
    Lars Ehlers
    Lars H. Rasmussen
    Giuseppe Boriani
    Gregory Y. H. Lip
    [J]. PharmacoEconomics, 2013, 31 : 971 - 980
  • [10] Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants
    Kasmeridis, Charalampos
    Apostolakis, Stavros
    Ehlers, Lars
    Rasmussen, Lars H.
    Boriani, Giuseppe
    Lip, Gregory Y. H.
    [J]. PHARMACOECONOMICS, 2013, 31 (11) : 971 - 980
12345